ACTRN12616001474448尚未招募未知
Pharmacist involvement to enhance identification and management of patients at discharge from hospital with increased risk of medication related problems and effect on quality of life and readmission to hospital: a double arm, randomised clinical trial.
Health Research South0 个研究点目标入组 700 人开始时间: 2016年10月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Eligible participants are adult (over 18 years) patients being treated on the Internal Medicine ward at Dunedin Hospital who are identified as being high risk for readmission by an electronic prioritisation tool. Patients meet inclusion criteria if they are allocated a certain score using a prioritisation tool on admission. The cut off score for inclusion is still to be decided (the electronic tool validation is underway currently).
排除标准
- •Patients who don't meet a certain score by the electronic prioritization tool (that identifies those at high risk for readmission) will be excluded from the study. Those who are unable to provide informed consent will be excluded from the study.
研究者
相似试验
已完成
不适用
Development of intervention tool and its effect on health care of patients with dyslipidemia by community pharmacistsDyslipidemiaJPRN-UMIN000044945Showa University40
终止
不适用
Enhancing Pharmacist Involvement in Care - Medication Assisted Treatment for Opioid Dependence (EPIC-MATOD) Implementation StudyOpioid dependencePublic Health - Health service researchMental Health - AddictionACTRN12621000871842Monash University85
尚未招募
1 期
The role of pharmacist for enhancing medication adherence in COPD (Chronic Obstructive Pulmonary Diseases) patients in pakistaChronic Obstructive Pulmonary Disease (COPD).Chronic obstructive pulmonary disease, unspecifiedJ44.9IRCT20220516054875N1Quaid-i-Azam University , Islamabad150
尚未招募
不适用
A combined, tailored pharmacist intervention with dose optimization of phosphate binding drugs to improve phosphate control in patients on dialysis.NL-OMON24286Franciscus Gasthuis and Vlietland45
已完成
不适用
Influence investigation by the pharmacist follow after the medicatioDiabetesJPRN-UMIN000042922others Chiba Pharmaceutical Association37